title: Achievement of national cholesterol education program goals by patients with dyslipidemia in rural ambulatory care settings.
abstract: The Third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program provides guidelines for managing dyslipidemia; however, studies from large centers find that most dyslipidemic patients fail to achieve management goals. Few data exist on lipid management in rural settings. To determine the proportion of rural dyslipidemic patients achieving ATP III goals, records of 461 patients were reviewed from 4 practices. Only 54% of the patients with dyslipidemia achieved ATP III goals. Patients with diabetes or with a family history of premature coronary heart disease were less likely to achieve ATP III goals (odds ratio 0.56; 95% confidence interval, 0.38-0.84 and odds ratio 0.42; 95% confidence interval, 0.25-0.71, respectively). Patients taking statins were more likely to achieve goals (odds ratio 3.23; 95% confidence interval, 2.13-4.89). These results indicate that a significant proportion of patients with dyslipidemia in rural practices do not achieve management goals. Strategies to improve lipid management in rural practices are needed.
authors.affiliation: Jim and Pat Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, CT, USA. rqayyum@hotmail.com
authors.forename: Rehan
authors.initials: R
authors.lastname: Qayyum
authors.forename: Ashraf A
authors.initials: AA
authors.lastname: Chattha
authors.forename: Navneet
authors.initials: N
authors.lastname: Bhullar
authors.forename: Manny
authors.initials: M
authors.lastname: Katsetos
authors.forename: Peter
authors.initials: P
authors.lastname: Schulman
mesh_terms: D000124:Achievement; D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000592:standards; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D050171:Dyslipidemias / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006040:Goals; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010353:Patient Education as Topic / Q000592:standards; D015995:Prevalence; D015397:Program Evaluation; D012189:Retrospective Studies; D012307:Risk Factors; D019035:Rural Health Services / Q000592:standards; D016896:Treatment Outcome; D014903:West Virginia / Q000453:epidemiology
chemical_list: D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents